Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002
High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013
Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009
Clinical and functional profile of patients with non-cystic fibrosis bronchiectasis according to the presence of chronic bronchial infection Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019
The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005
Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007
Diagnostic and therapeutic difficulties in pulmonary aspergillosis (PA) in paediatric cystic fibrosis (CF) patients Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003